Clinical trials: Chronic Obstructive Pulmonary Diseases
Chronic Obstructive Pulmonary Disease (COPD)
Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)
This is a multicenter, randomized, double-blind, parallel group, chronic-dosing (24 weeks), placebo-controlled study to assess the efficacy and safety of Glycopyrrolate (GP and Formoterol Fumarate (FF) combination metered-dose…
- Trial name
- NCT01854658
- Testing
- GFF MDI (PT003), GP MDI (PT001), FF MDI (PT005)
- Where
- 113 sites in United States
- Volunteers
- 1,615 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
Evaluation of Clinical Effectiveness of Roflumilast in Routine Practice, in Chronic Obstructive Pulmonary Disease (COPD) Patients in Greece
The purpose of this study was to examine the characteristics of patients selected for treatment with roflumilast and the effectiveness and safety of roflumilast in patients with severe or very severe COPD treated in Hospital and…
- Trial name
- ATLAS (NCT02187926)
- Volunteers
- 2,577 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
Study is to show that QVA149 is superior to the standard of care, fluticasone/salmeterol, in patients with moderate to severe airflow limitation
- Trial name
- NCT01834885
- Testing
- QVA149, fluticasone/salmeterol
- Where
- 29 sites in Austria, Germany
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to compare the efficacy and safety/tolerability of indacaterol and glycopyrronium (QVA149) (fixed-dose combination) with fluticasone/salmeterol over a 26-week period in patients with moderate to…
- Trial name
- ILLUMINATE (NCT01315249)
- Testing
- indacaterol and glycopyrronium (QVA149), fluticasone/salmeterol
- Where
- 93 sites in Belgium, Czechia and 7 more
- Volunteers
- 523 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study assessed the efficacy, safety and tolerability of the co-administration of NVA237 plus indacaterol taken once daily versus indacaterol taken once daily in patients with moderate to severe Chronic Obstructive Pulmonary…
- Trial name
- GLOW6 (NCT01604278)
- Testing
- NVA237 50 µg and indacaterol 150 µg
- Where
- 80 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 449 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive, Enterovirus Infections
First-in-human Clinical Trial Evaluating CUR-N399 in Healthy Volunteers.
The purpose of the trial is to evaluate CUR-N399, a PI4KB inhibitor, in a first-in-human trial to evaluate the safety, tolerability and pharmacokinetics profile of single and multiple ascending doses in healthy adults.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Enterovirus Infections, Rhinovirus
- Trial name
- NCT05016687
- Testing
- CUR-N399
- Where
- Sweden
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Curovir AB
Pulmonary Disease, Chronic Obstructive
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
The primary objective of the trial is to determine the 24-hour FEV1-time profile of tiotropium + olodaterol FDC, administered once daily by the RESPIMAT Inhaler after 6 weeks of treatment.
- Trial name
- NCT01559116
- Testing
- tiotropium + olodaterol, tiotropium, olodaterol
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 219 people
- Sponsor
- Boehringer Ingelheim
Low Back Pain, Mechanical
Effectiveness of Tricortin 1000 in Patients Affected by Chronic Low Back Pain
PAES, double blind, double dummy, multicenter, randomized, controlled clinical study to demonstrate superiority of Tricortin 1000 over placebo in improvement in pain relief as change from baseline to 15 days in patients with…
- Trial name
- NCT04585334
- Testing
- Tricortin 1000, Itami
- Where
- 13 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Fidia Farmaceutici s.p.a.
COPD
Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The trial is designed to identify an appropriate dose of QAB149 for delivery via a multiple dose inhaler for use in the COPD Phase III program.
- Trial name
- NCT00098228
- Testing
- QAB149
- Where
- 54 sites in United States
- Volunteers
- 686 people
- Sponsor
- Novartis Pharmaceuticals
BPH, Nocturia
Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy
Benign prostate hypertrophy (BPH) and inflammation are common non-cancerous enlargement of the prostate, which result in urinary interference and incomplete drainage of the bladder.
- Conditions
- BPH, Nocturia, BPH With Urinary Obstruction, Prostatism
- Trial name
- SVF-BPN (NCT02961114)
- Testing
- Microcannula Harvest Adipose, Centricyte 1000, IV Sterile Normal Saline
- Where
- 2 sites in United States
- Sponsor
- Robert W. Alexander, MD, FICS
Chronic Obstructive Pulmonary Disease
A Clinical Trial of TQC3721 Suspension for Inhalation
To evaluate the safety, tolerability and pharmacokinetic characteristics of TQC3721 suspension for inhalation in single/multiple administration(s) in healthy subjects; to evaluate the safety,tolerability and efficacy TQC3721…
- Trial name
- NCT05051930
- Testing
- TQC3721 suspension for inhalation
- Where
- China
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Dose Finding Study in COPD
The primary objective of this study is to determine the optimum dose of BEA 2180 BR inhalation solut ion delivered by the Respimat ? inhaler once daily for four weeks in patients with COPD.
- Trial name
- NCT00122434
- Testing
- BEA 2180 BR, tiotropium
- Where
- 43 sites in United States, Belgium and 1 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
This is a 12-week (with an extension to 52 weeks in a subset of participants) study comparing the safety of BGF MDI HFO twice daily (BID) with BGF MDI HFA BID in participants with moderate to very severe COPD.
- Trial name
- NCT05573464
- Testing
- BGF MDI HFO 320/14.4/9.6 μg, BGF MDI HFA 320/14.4/9.6 μg
- Where
- 91 sites in United States, Argentina and 7 more
- Volunteers
- 559 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Prednisolone Novel Endpoint Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Prednisolone will be used as a model medication to identify new clinical outcomes for future evaluation of new therapies in short-term studies (up to 4 weeks) in patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT00379730
- Testing
- Prednisolone
- Where
- 5 sites in Argentina, Chile and 2 more
- Volunteers
- 90 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study was intended to assess how well inhaled NVA237 opens up the airways of patients with mild, moderate or severe COPD over a 24 hour period after a 14 day treatment period.
- Trial name
- NCT00856193
- Testing
- NVA237
- Where
- 2 sites in United States, Germany
- Volunteers
- 33 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease
The Effect of NIV on QoL and Exercise Capacity in a COPD Exercise Rehabilitation Program
This trial hopes to demonstrate the effect of 4 weeks of outpatient exercise rehabilitation on COPD patients. In particular the effect on: the amount of daily physical activity Quality of life The 6-minute walk distance Time to…
- Trial name
- NCT02100709
- Testing
- BiLevel Noninvasive Ventilation
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- ResMed
Pulmonary Disease, Chronic Obstructive
GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
This study evaluates the safety of medicine on COPD (Chronic Obstructive Pulmonary Disease). This study will last up to 56 weeks, and subjects will visit the clinic 16 times.
- Trial name
- NCT00269087
- Testing
- fluticasone propionate/salmeterol combination DISKUS
- Where
- 5 sites in Japan
- Volunteers
- 122 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)
To compare the efficacy and safety of tiotropium plus formoterol in comparison to salmeterol plus fluticasone in COPD patients.
- Trial name
- NCT00239421
- Testing
- Test: Tiotropium 18 µg per day (one inhalation capsule) plus 12 µg formoterol twice daily (two times one inhalation capsule), Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d.
- Where
- 56 sites in Austria, Belgium and 6 more
- Volunteers
- 605 people
- Sponsor
- Boehringer Ingelheim
Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease
The primary purpose of the study is to determine whether lemborexant increases the apnea hypopnea index (AHI) on Day 8 of treatment in adult and elderly participants (adults greater than or equal to [>=] 45 to less than [<] 65…
- Conditions
- Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive, Respiration Disorders
- Trial name
- NCT04647383
- Testing
- Lemborexant 10 mg
- Where
- 11 sites in United States
- Volunteers
- 63 people
- Sponsor
- Eisai Inc.
Chronic Obstructive Pulmonary Disease
Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study was designed to obtain data about the efficacy and safety of 3 doses of indacaterol (150, 300, and 600 µg) in Japanese patients with chronic obstructive pulmonary disease (COPD) so that optimal dose(s) could be chosen…
- Trial name
- NCT00403845
- Testing
- Indacaterol 150 μg, Indacaterol 300 μg
- Where
- 8 sites in Japan
- Volunteers
- 50 people
- Sponsor
- Novartis